Mechanism(s) involved in opioid drug abuse modulation of HAND

Current HIV Research

Volumn 10, Issue 5, 2012, Pages 469-477

  Dutta, Raini ^a   Roy, Sabita ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Astrocyte; HAND; Microglia; Neuron; Opioid; Opportunistic infection; TLR

Indexed keywords

OPIATE; TOLL LIKE RECEPTOR;

ASTROCYTE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG ABUSE; DRUG TRAFFIC; EPIDEMIOLOGICAL DATA; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; MICROGLIA; MORBIDITY; MORTALITY; NEUROPATHOLOGY; OPIATE ADDICTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ASTROCYTES; BACTERIAL INFECTIONS; BLOOD-BRAIN BARRIER; DISEASE PROGRESSION; HEPATITIS, VIRAL, HUMAN; HIV-1; HUMANS; IMMUNOSUPPRESSION; MICROGLIA; SUBSTANCE-RELATED DISORDERS; TOLL-LIKE RECEPTORS;

EID: 84866334781     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802138805     Document Type: Review

References (101)

1. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-1028.
2. Vlahov D, Robertson AM and Strathdee SA. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis 2010; 50 Suppl 3: S114-S121.
3. Compton WM and Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83 Suppl 1: S4-S7.
4. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O and Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280: 544-546.
5. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
6. Moore RD, Keruly JC and Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35: 46-51.
7. Poundstone KE, Chaisson RE and Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15: 1115-1123.
8. Malta M, Strathdee SA, Magnanini MM and Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-1257.
9. Bruce RD and Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21: 149-179
10. Murray M, Hogg R, Lima V, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2012;13(2):89-97.
11. Wang X, Tan N, Douglas SD, Zhang T, Wang YJ and Ho WZ. Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells. J Leukoc Biol 2005; 78: 772-776.
12. Wang X, Douglas SD, Peng JS, et al. Naltrexone inhibits alcoholmediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol 2006; 79: 1166-1172.
13. Purohit V, Rapaka R and Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011; 44: 102-110.
14. Quaglio G, Lugoboni F, Talamini G, Lechi A and Mezzelani P. Prevalence of tuberculosis infection and comparison of multiplepuncture liquid tuberculin test and Mantoux test among drug users. Scand J Infect Dis 2002; 34: 574-576.
15. Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 2002; 31 Suppl 2: S62-S69.
16. Reichman LB, Felton CP and Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139: 337-339.
17. Wang J, Barke RA, Charboneau R and Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005; 174:426-434.
18. Wang J, Barke RA, Charboneau R, Schwendener R and Roy S. Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9- NF-kappa B signaling. J Immunol 2008; 180: 3594-3600.
19. Perry VH, Cunningham C and Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161-167.
20. Dunn N, Mullee M, Perry VH and Holmes C. Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis Assoc Disord 2005; 19: 91-94.
21. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D and Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 788-789.
22. Power C and Johnson RT. Neuroimmune and neurovirological aspects of human immunodeficiency virus infection. Adv Virus Res 2001; 56: 389-433.
23. Lindl KA, Marks DR, Kolson DL and Jordan-Sciutto KL. HIVassociated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 2010; 5: 294-309.
24. Krebs FC, Ross H, McAllister J and Wigdahl B. HIV-1-associated central nervous system dysfunction. Adv Pharmacol 2000; 49: 315-385.
25. Kolson DL, Lavi E and Gonzalez-Scarano F. The effects of human immunodeficiency virus in the central nervous system. Adv Virus Res 1998; 50: 1-47.
26. Ozdener H. Molecular mechanisms of HIV-1 associated neurodegeneration. J Biosci 2005; 30: 391-405.
27. Jones G and Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis 2006; 21: 1-17.
28. Bokhari SM, Yao H, Bethel-Brown C, et al. Morphine enhances Tat-induced activation in murine microglia. J Neurovirol 2009; 15: 219-228.
29. Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol 2011; 6: 442-445.
30. Brack A, Rittner HL and Stein C. Immunosuppressive effects of opioids-clinical relevance. J Neuroimmune Pharmacol 2011; 6: 490-502.
31. Madera-Salcedo IK, Cruz SL and Gonzalez-Espinosa C. Morphine decreases early peritoneal innate immunity responses in Swiss- Webster and C57BL6/J mice through the inhibition of mast cell TNF-alpha release. J Neuroimmunol 2011; 232: 101-107.
32. Olin M, Oh S, Roy S, Peterson P and Molitor T. Morphine Induces Splenocyte Trafficking into the CNS. J Neuroimmune Pharmacol 2011; 7(2):436-443
33. Mahajan SD, Aalinkeel R, Sykes DE, et al. Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability. J Clin Immunol 2008; 28: 528-541.
34. Turchan-Cholewo J, Dimayuga FO, Gupta S, et al. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 2009; 108: 202-215.
35. Turchan-Cholewo J, Dimayuga FO, Ding Q, et al. Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res 2008; 86: 2100-2110.
36. Ellis R, Langford D and Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33-44.
37. Kanmogne GD, Kennedy RC and Grammas P. HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIVassociated dementia. J Neuropathol Exp Neurol 2002; 61: 992-1000.
38. Kanmogne GD, Primeaux C and Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIVassociated dementia. J Neuropathol Exp Neurol 2005; 64: 498-505.
39. Andras IE, Pu H, Deli MA, Nath A, Hennig B and Toborek M. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003; 74: 255-265.
40. Lynch JL and Banks WA. Opiate modulation of IL-1alpha, IL-2, and TNF-alpha transport across the blood-brain barrier. Brain Behav Immun 2008; 22: 1096-1102.
41. Kaul M and Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol 2006; 1: 138-151.
42. Liu NQ, Lossinsky AS, Popik W, et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogenactivated protein kinase signaling pathway. J Virol 2002; 76: 6689-66700.
43. Albright AV, Soldan SS and Gonzalez-Scarano F. Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol 2003; 9: 222-227.
44. Gonzalez-Scarano F and Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
45. Glass JD, Fedor H, Wesselingh SL and McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38: 755-762.
46. Adle-Biassette H, Chretien F, Wingertsmann L, et al. Neuronalapoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol 1999; 25: 123-133.
47. Corr P. Imaging of neuro-AIDS. J Psychosom Res 2006; 61: 295-299.
48. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002; 186 Suppl 2: S193-S8.
49. Chang HC, Samaniego F, Nair BC, Buonaguro L and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparansulfate proteoglycans through its basic region. AIDS 1997; 11: 1421-31
50. Lipton SA and Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995; 332: 934-940.
51. Rock RB and Peterson PK. Micro glia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol 2006; 1: 117-126.
52. Burbassi S, Aloyo VJ, Simansky KJ and Meucci O. GTPgammaS incorporation in the rat brain: a study on mu-opioid receptors and CXCR4. J Neuroimmune Pharmacol 2008; 3: 26-34.
53. Happel C, Steele AD, Finley MJ, Kutzler MA and Rogers TJ. DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-beta1. J Leukoc Biol 2008; 83: 956-963.
54. Mahajan SD, Aalinkeel R, Reynolds JL, et al. Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res 2005; 3: 277-288.
55. Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE and Nair MP. Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 2005; 115: 323-332.
56. Steele AD, Henderson EE and Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 2003; 309: 99-107.
57. Suzuki S, Carlos MP, Chuang LF, Torres JV, Doi RH and Chuang RY. Methadone induces CCR5 and promotes AIDS virus infection. FEBS Lett 2002; 519: 173-177.
58. Miyagi T, Chuang LF, Doi RH, Carlos MP, Torres JV and Chuang RY. Morphine induces gene expression of CCR5 in human CEMx174 lymphocytes. J Biol Chem 2000; 275: 31305-3110.
59. Hu S, Chao CC, Hegg CC, Thayer S and Peterson PK. Morphine inhibits human microglial cell production of, and migration towards, RANTES. J Psychopharmacol 2000; 14: 238-243.
60. Zou S, Fitting S, Hahn YK, et al. Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at muopioid receptor-expressing glia. Brain 2011; 134(Pt 12): 3616-3631.
61. El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE and Hauser KF. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 2006; 178: 9-16.
62. El-Hage N, Wu G, Wang J, et al. HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 2006; 53: 132-146.
63. Avdoshina V, Biggio F, Palchik G, Campbell LA and Mocchetti I. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 2010; 58: 1630-1639.
64. Wang X, Ye L, Zhou Y, Liu MQ, Zhou DJ and Ho WZ. Inhibition of anti-HIV microRNA expression: a mechanism for opioidmediated enhancement of HIV infection of monocytes. Am J Pathol 2011; 178: 41-47.
65. Atwood WJ, Tornatore CS, Meyers K and Major EO. HIV-1 mRNA transcripts from persistently infected human fetal astrocytes. Ann N Y Acad Sci 1993; 693: 324-325.
66. Yao K, Akyani N, Donati D, et al. Detection of HHV-6B in postmortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis. J Clin Virol 2006; 37 Suppl 1: S57-S62.
67. Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D and Major EO. Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 2004; 78: 7319-7328.
68. Epstein LG, Sharer LR, Cho ES, Myenhofer M, Navia B and Price RW. HTLV-III/LAV-like retrovirus particles in the brains of patients with AIDS encephalopathy. AIDS Res 1984; 1: 447-454.
69. Mirra SS and del Rio C. The fine structure of acquired immunodeficiency syndrome encephalopathy. Arch Pathol Lab Med 1989; 113: 858-865.
70. Gyorkey F, Melnick JL and Gyorkey P. Human immunodeficiency virus in brain biopsies of patients with AIDS and progressive encephalopathy. J Infect Dis 1987; 155: 870-876.
71. Wiley CA, Schrier RD, Nelson JA, Lampert PW and Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986; 83: 7089-7093.
72. Bagasra O, Lavi E, Bobroski L, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immuno histochemistry. AIDS 1996; 10: 573-585.
73. Nuovo GJ and Alfieri ML. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Mol Med 1996; 2: 358-366.
74. Nuovo GJ, Gallery F, MacConnell P and Braun A. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-alpha RNA in the central nervous system. Am J Pathol 1994; 144: 659-666.
75. Sharer LR, Saito Y, Epstein LG and Blumberg BM. Detection of HIV-1 DNA in pediatric AIDS brain tissue by two-step ISPCR. Adv Neuroimmunol 1994; 4: 283-285.
76. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT and Glass JD. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 1996; 39: 705-711.
77. Hao HN and Lyman WD. HIV infection of fetal human astrocytes: the potential role of a receptor-mediated endocytic pathway. Brain Res 1999; 823: 24-32.
78. Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR and Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol 1997; 151: 1341-1351.
79. Seilhean D, Dzia-Lepfoundzou A, Sazdovitch V, et al. Astrocytic adhesion molecules are increased in HIV-1-associated cognitive/motor complex. Neuropathol Appl Neurobiol 1997; 23: 83-92.
80. El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A and Hauser KF. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 2005; 50: 91-106.
81. El-Hage N, Bruce-Keller AJ, Yakovleva T, et al. Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca(2+)](i), NF-kappaB trafficking and transcription. PLoS One 2008; 3: e4093.
82. Carpentier PA, Duncan DS and Miller SD. Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun 2008; 22: 140-147.
83. Lehnardt S, Lehmann S, Kaul D, et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007; 190: 28-33.
84. Bailey SL, Carpentier PA, McMahon EJ, Begolka WS and Miller SD. Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol 2006; 26: 149-88.
85. McKimmie CS and Fazakerley JK. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J Neuroimmunol 2005; 169: 116-25.
86. Bsibsi M, Ravid R, Gveric D and van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-1021.
87. Laflamme N and Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gramnegative bacterial cell wall components. FASEB J 2001; 15: 155-163.
88. Babcock AA, Kuziel WA, Rivest S and Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 2003; 23: 7922-7930.
89. Babcock AA, Wirenfeldt M, Holm T, et al. Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J Neurosci 2006; 26: 12826-12837.
90. Quandt J and Dorovini-Zis K. The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J Neuropathol Exp Neurol 2004; 63: 350-362.
91. Trifilo MJ and Lane TE. The CC chemo kin e lig and 3 regulates CD11c+CD11b+CD8alpha- dendritic cell maturation and activation following viral infection of the central nervous system: implications for a role in T cell activation. Virology 2004; 327: 8-15.
92. Heggelund L, Muller F, Lien E, et al. Increased expression of tolllike receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin Infect Dis 2004; 39: 264-269.
93. Heggelund L, Damas JK, Yndestad A, et al. Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induceschemokine responses: possible pathogenic consequences. Clin Exp Immunol 2004; 138: 116-121.
94. El-Hage N, Podhaizer EM, Sturgill J and Hauser KF. Toll-like Receptor Expression and Activation in Astroglia: Differential Regulation by HIV-1 Tat, gp120, and Morphine. Immunol Invest 2011; 40(5): 498-522.
95. Chen L, Shi W, Li H, et al. Critical role of toll-like receptor 9 in morphine and Mycobacterium tuberculosis-Induced apoptosis in mice. PLoS One 2010; 5: e9205.
96. He L, Li H, Chen L, et al. Toll-like receptor 9 is required for opioid-induced microglia apoptosis. PLoS One 2011; 6: e18190.
97. Fitting S, Xu R, Bull C, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010; 177: 1397-410.
98. Malik S, Khalique H, Buch S and Seth P. A Growth Factor Attenuates HIV-1 Tat and Morphine Induced Damage to Human Neurons: Implication in HIV/AIDS-Drug Abuse Cases. PLoS One 2011; 6: e18116.
99. Podhaizer EM, Zou S, Fitting S, et al. Morphine and gp120 Toxic Interactions in Striatal Neurons are Dependent on HIV-1 Strain. J Neuroimmune Pharmacol 2011.
100. Mishra BB, Mishra PK and Teale JM. Expression and distribution of Toll-like receptors in the brain during murine neurocysticercosis. J Neuroimmunol 2006; 181: 46-56.
101. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104: 13798-803.